Semaglutide News and Research

Latest Semaglutide News and Research

Study offers insight into state Medicaid coverage for anti-obesity drugs

Mounting evidence suggests that FDA-approved weight loss medications, such as Wegovy, not only help patients lose weight but also protect against complications from obesity such as cardiovascular disease.

14 Mar 2024

New research sheds light on how GLP-1 obesity drugs may change food cravings

GLP-1 analog treatments potentially alter food preferences and reduce obesity by decreasing appetite and food consumption, with further research needed for long-term weight maintenance using objective measures.

10 Mar 2024

Diabetes drug dulaglutide may reduce symptoms of depression

The current study highlighted the antidepressant effects of dulaglutide using the CMS depression model. Notably, the potential metabolisms that underlie the antidepressant effect of dulaglutide have been elucidated in this study.

8 Mar 2024

Study reveals mechanisms behind antidepressant effects of diabetes drug

Research in animals has shown that the diabetes drug dulaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist may reduce symptoms of depression.

6 Mar 2024

Study shows semaglutide as a safe and effective therapy for MASLD in people with HIV

A weekly injection of semaglutide was safe and reduced the amount of fat in the liver by 31% in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD), according to a presentation today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

5 Mar 2024

New hope for binge eating and bulimia: GLP-1 drugs could be the key

GLP-1 receptor agonists show promise in reducing binge eating behaviors in disorders like bulimia nervosa, offering a new avenue for treatment with minimal side effects.

4 Mar 2024

Gut bacteria diversity linked to body weight, athletes show healthier profiles

Systematic review reveals gut microbiome variations correlate with body composition changes across lifespan, highlighting differences between obese individuals and athletes.

29 Feb 2024

Exercise, GLP-1 receptor agonist, or combined approach explored in year-long study

Researchers compare the extent of weight loss after one-year termination of active intervention with GLP-1 receptor agonist, exercise, or combination.

29 Feb 2024

An Arm and a Leg: Wait, is Insulin cheaper now?

Pharmaceutical companies that manufacture insulin made headlines last year when they voluntarily agreed to provide discount cards that lower the monthly cost of insulin for many people to $35.

28 Feb 2024

Bariatric surgery outperforms medical management in long-term diabetes control

People with type 2 diabetes who underwent bariatric surgery achieved much better long-term blood glucose control compared to people who received medical management plus lifestyle interventions, according to a new study published in JAMA, or Journal of the American Medical Association, and funded by the National institute of Diabetes, Digestive and Kidney Diseases, part of The National Institutes of Health.

27 Feb 2024

Underutilized obesity treatments could transform patient health

When someone has obesity, losing even 5% of their body weight can make a major difference in their health -- especially if they can keep from regaining it.

21 Feb 2024

Lactocore Group leverages milk peptides to combat inflammaging

...

From Lactocore Group 21 Feb 2024

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.

7 Feb 2024

New weight loss drug may be an effective strategy for preventing or treating high blood pressure

The new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took the medication for about eight months, according to new research published today in Hypertension, an American Heart Association journal.

5 Feb 2024

Over 80% of semaglutide users achieve significant weight loss after 12 months, study finds

...

5 Feb 2024

What does the future hold for obesity medication development?

The safety, clinical implications, and challenges of obesity pharmacotherapies based on entero-pancreatic hormone- treatments.

5 Feb 2024

Breakthrough obesity treatments on the horizon, rivaling surgery's success

New obesity pharmacotherapies, including GLP-1 receptor agonists and combinations of entero-pancreatic hormones, show promise in achieving significant weight loss, potentially rivaling bariatric surgery's effectiveness.

4 Feb 2024

SGLT2 inhibitors linked to lower risk of kidney stones in patients with type 2 diabetes

Rates of kidney stones are on the rise in the United States and around the world. Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones.

31 Jan 2024

Fermented foods linked to mental health benefits through gut-brain connection

Researchers explore the mental health benefits of fermented foods on the microbiota-gut-brain axis, highlighting the need for further studies to understand their therapeutic potential.

29 Jan 2024

Study links GLP1 agonists to reduced risk of severe liver disease in diabetic patients

Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet in Sweden published in the journal Gut.

23 Jan 2024